Pipeline dossier

NIH & clinical-trial pipeline signals for Aktis Oncology, Inc. (AKTS)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for AKTS, mapped to public ticker AKTS (CIK 0002035832). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingAKTS35% conf

Aktis Oncology, Inc. (AKTS) — PHASE1 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-08-13 — 8-K 2.02,9.01 view ↗
2026-05-11 — 8-K 2.02,9.01 view ↗
2026-04-16 — 8-K 5.02,7.01,9.01 view ↗
2026-03-30 — 8-K 2.02,9.01 view ↗
2026-01-12 — 8-K 5.03,9.01 view ↗

JSON API for this entity →